Date updated:01-17-2008
Cramer recently focused on contract research organizations, or CROs. These companies allow big pharmaceuticals to outsource their clinical trial work to cut costs.

-
CVD
Covance Inc. - $45.86
- 0.00%
- $44.52
Cramer's favorite in this space is Covance (CVD). Covance, Cramer said, handles early and late stage testing and has a solid customer base. The company also has an immaculate balance sheet, according to Cramer. Covance has $250 million in cash, no debt and $300 million in expected free cash flow over the next two years. Cramer sees the potential for Covance to trade at 37 times this year's earnings, which translates to a target price of $115, or a 33% upside. Despite being just $1 off its 52-week high, Cramer said Covance "must be bought on any weakness."

-
CRL
Charles River Lab - $31.78
- 0.00%
- $31.39
Cramer also recommended Charles River Labs (CRL) as an early stage CRO play and Parexel (PRXL) as a pure-play late stage CRO.

-
PRXL
Parexel Internati - $11.22
- +3.51%
- $10.83
Cramer also recommended Charles River Labs (CRL) as an early stage CRO play and Parexel (PRXL) as a pure-play late stage CRO.

-
NVS
Novartis Ag Basel - $39.80
- 0.00%
- $39.26
He also still likes drugmaker Novartis (NVS) and retailer CVS Caremark (CVS). CVS is a stock that he also owns for his Action Alerts PLUS portfolio.

-
CVS
Cvs Caremark Corp - $31.34
- 0.00%
- $30.69
He also still likes drugmaker Novartis (NVS) and retailer CVS Caremark (CVS). CVS is a stock that he also owns for his Action Alerts PLUS portfolio.
- Cramer's Outsourcing R&D Stock Plays's Blog
- No Blogs Found
- Top Professional Portfolios
- 1. Navellier & Associ...
- 2. Highbridge Statistical...
- 3. Joel Greenblatt
- 4. Amana Trust Growth - A...
- 5. Fidelity International...
- show all
- Top Do-It-Yourself Portfolios
- » agtest1
- » Joy
- » tsamanuli Portfolio 1
- » brueckenc Portfolio 1
- » HMH1
- show all
- Most Viewed Portfolios
- » Warren Buffett
- » George Soros
- » T. Boone Pickens - BP Cap...
- » Carl Icahn
- » Renaissance Technologies
- show all
By Stockpickr Staff Posted on July 2, 2009 Developments in the stem cell world are starting to get very interesting. On Tuesday, General Electric (GE) signed an exc...
By Rebecca Corvino Posted on July 2, 2009 Every day, Stockpickr members are creating and sharing stock ideas with each other through various platforms. If you're not al...
By Rebecca Corvino Posted at 12:30 p.m. EDT on July 2, 2009 Making Thursday's headlines and sending stocks lower were reports that June saw the loss of 467,000 more job...
By Stockpickr Staff Posted on July 2, 2009 Some investors assume that at this time of year, it's the summer doldrums for the stock market. After all, as the saying goe...
A. commodities also down across the board.
i think guidance will be the real market
mover, cause i think we only have q3
left for peoples patience to run out.
mike
A. The only one I own : SLX,
too hard pick a winner out all of them
Here are some of the biggest stocks that made the 52-week high list on July 1, 2009. more
Here are some of the largest % gainers from July 1, 2009. more
Analyst Downgrades for July 1, 2009. Read more here. more






Comments not available